Highest-materiality recent filing
Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition
Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.
Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B
Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).
Zoetis issues $2B of 0.25% convertible notes due 2029; proceeds for stock buyback and capped calls
Aggregate principal $2.0B (including $250M option exercised); 0.25% semi-annual interest; matures June 15, 2029.
Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed
Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).
Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance
Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.
Zoetis Q1 2025 revenue $2.2B (+9% organic), adj EPS $1.48; affirms 6-8% organic growth for FY
Revenue $2.2B (+1% reported, +9% organic operational); net income $631M, diluted EPS $1.41.
Zoetis Q4 revenue $2.3B (+5%), adj. EPS $1.40; FY2025 guidance organic growth 6-8%
Q4 2024 revenue $2.3B (+5% reported, +9% organic operational); reported EPS $1.29, adjusted EPS $1.40.
Zoetis announces leadership reshuffle: CTO Mamilli leaving, new CCO and US President appointed
Wafaa Mamilli (EVP, Chief Digital & Technology Officer) to leave early 2025 for external opportunity; Keith Sarbaugh promoted to EVP and Chief Digital & Technology Officer, effective immediately.
Zoetis Q3 revenue $2.4B (+11%); adjusted EPS $1.58; FY guidance raised
Revenue $2.4B, +11% reported (+14% operational); GAAP EPS $1.50 (+16% YoY).
Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance
Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.
Zoetis announces $6B share repurchase program, replacing $3.5B program expected to finish in 2024
Board approved up to $6 billion in share repurchases with no expiration date.
Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported
Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.
Zoetis Q4 2023 revenue $2.2B (+8%), adj. EPS $1.24; FY2024 guidance $9.075-9.225B
Q4 revenue $2.2B (+8% reported & operational); net income $525M ($1.14 diluted EPS), up 14% and 15% respectively.
Zoetis Q3 revenue $2.2B (+8% operational), EPS $1.29; narrows FY guidance
Revenue $2.2B, up 7% reported / 8% operational; net income $596M ($1.29 EPS), +13%/+14%.
Revenue $2.2B, +6% reported, +9% operational; net income $671M ($1.45 EPS) +27%/29%.
Zoetis Investor Day targets mid-to-high single-digit revenue growth, $1B+ peak OA pain franchise
Annual revenue growth target of mid-to-high single digits over next 3-5 years.
Zoetis Q1 revenue $2.0B (+1% reported, +4% operational); adj. EPS $1.31, down 1% operationally
Reported net income $552M ($1.19 diluted EPS), down 7% and 6% YoY respectively.
Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B
Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).
Zoetis Q3 2022 revenue $2.0B (+1%), net income $529M; cuts FY 2022 guidance
Revenue $2.0B, +1% reported (+5% operational); net income $529M ($1.13 diluted EPS), down 4% and 3%.
Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.
Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.
On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity.
As a result of Ms. Mamilli’s planned departure, Keith Sarbaugh has been promoted to the role of Executive Vice President and Chief Digital & Technology Officer effective immediately.
On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement
Effective May 21, 2024, Dr. Linda Rhodes retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective April 16, 2024, Heidi C. Chen will cease her role as Executive Vice President, General Counsel and Corporate Secretary, and Business Lead of Human Health Diagnostics of Zoetis Inc. (the “Company”).
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations, will serve as interim General Counsel and Corporate Secretary while the Company conducts a search for Ms. Chen’s permanent replacement.
On April 1, 2024, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Gavin D.K. Hattersley to the Board,
On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the “Company”), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company.
William (“Chip”) Dorsey, Vice President, Finance will serve as interim head of U.S. Operations and Global Diagnostics while the Company conducts a search for Mr. David’s permanent replacement.
Max materiality 0.85 · Median 0.50 · Most common event dividend